



- Twist Bioscience have launched a new research panel which can identify multiple respiratory diseases including novel coronavirus. This is not an alternative to clinical test but is helpful in detecting early signs of outbreak.
- ADIDAS AG v. NIKE, INC (United States Courts of Appeal for Federal Circuit) – U.S. Patent Nos. 7,814,598 and 8,266,749 owned by Nike, Inc. sharing a specification and are directed to methods of manufacturing an article of footwear with a textile upper. The process involves removing a textile element from the textile structure and incorporating it into an upper of the article of footwear. Adidas challenged the claims as obvious in view of the combination of U.S. Patent Nos. 3,985,003 (Reed) and 5,345,638 (Nishida) as Ground 1 and the combination of Nishida and U.S. Patent Nos. 4,038,840 (Castello) and 6,330,814 (Fujiwara) as Ground 2. Board noted that embodiments of Reed teach pre-seaming” whereas Nishida involves seaming the textile element after it has been cut from the textile structure and that there is lack of motivation to combine both of them because of unitary construction limitation. Board determined that combining Reed with Nishida would “*require the alteration of the principles of operation of Reed or would render Reed inoperable for its intended purpose.*” As Adidas failed to reconcile these differences, Court on appeal concluded that the Board’s motivation to combine findings are supported by substantial evidence.



IP
NEWS

- Elon Musk’s company SpaceX is starting beta test for its Starlink Satellite Constellation promising to provide reliable and cheap high speed internet to all location on earth. Seattle and Germany is running the first beta test of Starlink. It is claimed to have one gigabit per second.

CYBER
NEWS

UPTO has issued a patent on private blockchains to Ai-Blockchain, a leading provider of custom artificial intelligence driven and blockchain solutions to clients such as financial exchanges, hospitals, media content providers and supply chain platforms. U.S. Patent No. 10,579,974, entitled "SYSTEMS, METHODS, AND PROGRAM PRODUCTS FOR A DISTRIBUTED DIGITAL ASSET NETWORK WITH RAPID TRANSACTION SETTLEMENTS," was issued on March 3, 2020, this patent is directed to AiB’s core technology which enables private blockchains to transact digital assets quickly between parties such as digital rights management for media companies, financial exchanges and customers, healthcare institutions and physicians, and supply chains and retailers.

Science & Technology

- Injecting drug filled microscopic bubbles has long been the way to treat cancer requiring ultrasound to track these microbubbles and bursting them by increasing the frequency when reaches the target location of tumor. Researchers of Tel Aviv University have developed new method of injecting microbubbles directly to the tumor and making those bubbles to explode. This would destroy about 80% of the tumor cells. Further this explosion would create pores in the membrane of the remaining tumor cells through which immunotherapy gene, which have been injected along with the microbubbles, would enter the tumor cell triggering the immune system to destroy the remaining ones. This method would be particularly useful in treatment for brain-related diseases such as brain tumor and other neurodegenerative conditions such as Alzheimer's and Parkinson's diseases, where blood-brain barrier does not allow for medications to penetrate through, but microbubbles can temporary open the barrier through creation of pores by exploding, enabling the arrival of the treatment to the target area without the need for an invasive surgical intervention.
- Medtronic have came up with Deep Brain Stimulation implant with ability to read, capture and transmit a patient’s brain signals during therapy. This implant is shaped like a small pacemaker; the main device is placed under the skin of the chest, with small electrical leads connected to different regions of the brain. The system is also compatible with full-body MRI scans. This has been approved by FDA.